DGKα-IN-2 (example 48), a potent DGKα inhibitor with an IC50 of 0.9 nM, exhibits potential for cancer and immunological research by significantly augmenting the anti-tumor efficacy of anti-PD-1 therapy through the amplification of T cell proliferation and function.